Surendra Basti, MD
Ophthalmology · Chicago, ILNPI 1619963873
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (47.0%), consulting fees and speaking fees — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 46.5% of the total. Among ophthalmology clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 133 payments — averaging $950.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$59K
- Bausch & Lomb Americas Inc.$33K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$30K
- Alcon$3K
- Carl Zeiss Meditec, Inc.$261
- Carl Zeiss Meditec USA, Inc.$123
- plus $252 from 5 others
Across 1 payment — averaging $5300.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Johnson & Johnson Surgical Vision, Inc.$5K
What the payments were for
- Consulting fees$48,20438%
- Speaking & faculty fees$12,81510%
- Grants$59,50047%
- Travel & lodging$2,5362%
- Food & beverage$3,4083%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 75 | $58,837 |
| Bausch & Lomb Americas Inc. | 12 | $33,417 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $30,179 |
| Alcon | 17 | $3,394 |
| Carl Zeiss Meditec, Inc. | 7 | $261 |
| Carl Zeiss Meditec USA, Inc. | 4 | $123 |
| Johnson & Johnson Vision Care, Inc. | 2 | $95 |
| Johnson & Johnson | 1 | $75 |
| Rxsight Inc | 2 | $39 |
| Beaver-visitec International, Inc. | 1 | $24 |
| Novartis | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Tecnis IOL$42,712
- Baerveldt Glaucoma Implant (250)$37,627
- Compact Intuitiv$37,627
- Catalys Laser System$8,328
- Baerveldt Glaucoma Implants$7,150
- COMPACT INTUITIV Phacofragmentation System$7,150
- Whitestar Phacoemulsficiation System$3,500
- VERITAS Vision System$2,466
- CATALYS SYSTEM$2,120
- VICTUS$2,000
- STELLARIS PC$2,000
- CRYSTALENS$2,000
- TRULIGN TORIC$2,000
- ELITA$1,547
- ENVISTA$1,000
- Tecnis Simplicity$600
- LOTEMAX$525
- VYZULTA$525
- PROLENSA$525
- LUMERA$104
How this compares
$126,463 in reported general payments places this provider in the 95th percentile of 773 ophthalmology providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 95 | $72,429 |
| XiidraLifitegrast | 39 | $30,365 |
| Cyclosporine | 63 | $20,510 |
| MieboPerfluorohexyloctane/Pf | 24 | $18,276 |
| Restasis MultidoseCyclosporine | 25 | $16,504 |
| Prednisolone Acetate | 260 | $10,379 |
| LumiganBimatoprost | 12 | $6,029 |
| Bromfenac Sodium | 22 | $3,594 |
| Fluorometholone | 42 | $2,821 |
| Ketorolac Tromethamine | 82 | $1,571 |
| ValacyclovirValacyclovir Hcl | 21 | $834 |
| Brimonidine Tartrate | 34 | $767 |
| Latanoprost | 45 | $715 |
| Timolol Maleate | 54 | $587 |
| MoxifloxacinMoxifloxacin Hcl | 19 | $295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $33,417 | $48,64163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 773 ophthalmology providers in Illinois.
Other ophthalmology in Chicago
- Seenu HariprasadChicago$2.3M
- Yannek LeidermanChicago$312K
- Asim FarooqChicago$270K
- Dilraj GrewalChicago$188K
- Ahmad ArefChicago$179K
- Robert SchroederChicago$153K
- Jennifer LimChicago$150K
- Allen PuttermanChicago$94K
- Maria CortinaChicago$88K
- Robison ChanChicago$81K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.